Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fenoldopam→

Fenoldopam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
67227-56-9
Molecular formula
C16H16ClNO3
Molecular weight
305.75 g/mol
Drug class
Selective dopamine D1-like receptor agonistshort-acting intravenous vasodilator
Mechanism of action
Stimulates peripheral D1-like dopamine receptors, producing arterial vasodilation, increased renal blood flow and natriuresis. Its rapid onset and short duration make it suitable for titratable intravenous blood-pressure reduction.
Indications / reported uses
  • Short-term hospital treatment of severe hypertension when rapid, titratable blood-pressure reduction is required; continuous blood-pressure and heart-rate monitoring are necessary

Sources: US DailyMed — CORLOPAM (fenoldopam) · NLM MeSH — Fenoldopam · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fenoldopam Environmental Risk Assessment (ERA) (the Fenoldopam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.